MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.370
+0.090 (7.03%)
At close: Nov 20, 2026, 4:00 PM EST
1.350
-0.020 (-1.46%)
After-hours: Nov 20, 2026, 7:03 PM EST
MaxCyte Revenue
MaxCyte had revenue of $10.15M in the quarter ending September 30, 2026, with 48.66% growth. This brings the company's total for the last twelve months to $34.37M, down -0.13% year-over-year. In the year 2025, MaxCyte had annual revenue of $33.03M, down -14.50%. That makes MaxCyte the 30,564th largest company in the world by revenue and 4,025th in the United States.
Revenue (ttm)
$34.37M
Revenue Growth
-0.13%
P/S Ratio
4.12
Revenue / Employee
$377,736
Employees
91
Market Cap
141.45M
Revenue by Geography
- United States 21.08M 63.8%
- Outside The United States 11.95M 36.2%
Fiscal year ended Dec 31, 2025 See the full MaxCyte breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.03M | -5.60M | -14.50% |
| Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
| Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
| Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
| Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
| Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
| Dec 31, 2019 | 21.62M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 355.06M |
| Neuronetics | 159.76M |
| Quanterix | 148.15M |
| RxSight | 121.83M |
| Pulmonx | 88.78M |
| Electromed | 75.57M |
| Apyx Medical | 59.57M |
| TriSalus Life Sciences | 46.39M |
MXCT News
- 3 days ago - MaxCyte Transcript: 2026 Stephens Annual Investment Conference | NASH2026 - Transcripts
- 10 days ago - MaxCyte Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 11 days ago - MaxCyte to acquire Akron BioProducts for $151.8M - TheFly
- 11 days ago - MaxCyte reports Q3 EPS (5c), consensus (8c) - TheFly
- 11 days ago - MaxCyte now sees 2026 revenue ex-items $34.5M, consensus $32.2M - TheFly
- 11 days ago - MaxCyte Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - MaxCyte Earnings release: Q3 2026 - Filings
- 11 days ago - MaxCyte Quarterly report: Q3 2026 - Filings